In today’s ACT Brief, we examine how AI and functional service partners are reshaping global pharmacovigilance, look at new ...

The FDA has approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for the treatment of adolescents two years and older, teens, and adults living with spinal muscular atrophy (SMA) with a ...

Artificial intelligence (AI) seems to be everywhere, but what is its future in clinical research? Clinical research inherently involves humans. However, it also involves numerous administrative ...